Evidence map›Paper›PMID 40550803›Full record

ArticleScientific reports2025

Eco-friendly spectrophotometric quantification of the potential combination of mirabegron and tamsulosin.

Omar M El-Abassy, Hanaa Saleh, Islam M Darwish, Eman A Bahgat

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Omar M El-AbassyPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt. omar-magdy@eru.edu.eg.
Hanaa SalehPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Islam M DarwishEgyptian Drug Authority, Giza, 12622, Egypt.
Eman A BahgatPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, men with overactive bladder have been prescribed mirabegron and tamsulosin for the treatment of benign prostatic hyperplasia. Highly efficient and environmentally sustainable spectrophotometric methods have been developed for the accurate determination of mirabegron and tamsulosin in their pure forms as well as within pharmaceutical formulations. This study presents three effective and simple spectrophotometric methods for the simultaneous quantification of mirabegron and tamsulosin. The current protocols have demonstrated validation for linearity across concentration ranges of 3-20 µg/mL for mirabegron and 2-40 µg/mL for tamsulosin, utilizing dual wavelength, ratio difference, and derivative ratio techniques. The coefficients of determination exceeded 0.999. The validation of these methodologies was conducted in accordance with the guidelines set forth by the International council for Harmonization (ICH). Quality control laboratories may utilize existing techniques to identify the binary combination because of their high accuracy and cheap cost. The evaluation of the environmental sustainability of the established approaches was conducted using AGREE, GAPI, MOGAPI and whiteness revealing their notable eco-friendliness. The proposed method was deemed practical after the evaluation carried out with the Blue Applicability Grade Index (BAGI) assessment.

Indexed as

AcetanilidesTamsulosinThiazolesHumansMaleProstatic HyperplasiaReproducibility of ResultsSpectrophotometryAcetanilidesmirabegronTamsulosinThiazolesDerivative ratioDual wavelengthMirabegronRatio differenceTamsulosin

Identifiers

PMID40550803
PMCPMC12185759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.